“

We could go public right now if we wanted but strategically and operationally it is best to stay private for now because we are well-financed and having a laser focus on execution when you are getting ready to launch a diabetes drug is a big benefit, at some point I'm sure we will be a public company. We hope when we do that we will have launched our first medicine and we have multiple exciting products coming through in the pipeline.